KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kopran Ltd filed its Annual Report for FY 2024-25 along with the Notice of its 66th AGM, scheduled for September 11, 2025 via video conferencing. On a consolidated basis, revenue was nearly flat at Rs. 63,358.64 lakhs (up 0.70% YoY), but net profit fell about 24% to Rs. 3,855.19 lakhs and EBITDA stood at Rs. 7,441 lakhs. On a standalone basis, revenue declined 21.81% to Rs. 27,691 lakhs and profit before tax dropped 19.59% to Rs. 3,579 lakhs, largely due to a 19.69% fall in the Formulations segment. The Board recommended a final dividend of Rs. 3.00 per share (30%), unchanged from the prior year. The company also announced a scheme of amalgamation to merge its diagnostic arm, Kopran Laboratories Limited, into Kopran Limited, and appointed Mr. Surendra Somani as Chairman and Managing Director effective January 1, 2026.
Mixed bag for shareholders — top-line held up on a consolidated basis but profitability came under pressure, with both standalone and consolidated profits declining sharply. A stable dividend and the ongoing merger suggest management confidence, but the weak formulations performance and lower margins may keep the stock under near-term scrutiny.